Abstract
We model the observed dynamics of COVID-19 in Mexico and Peru and explore the impact of hypothetical non-pharmaceutical interventions applied on key days of civic, religious, or political nature that increased contacts and transmission events. Using as a baseline the observed epidemic curve, we apply hypothetical reductions in the contact rates during the first year of the pandemic: i) near the beginning, ii) at the beginning of the second outbreak, and iii) end of the year. The effects of the interventions are different for Mexico and Peru but underlie the fact that strong early interventions do reduce the prevalence and, in general, allow for an epidemic evolution of relatively lower prevalence than interventions applied once the epidemic is underway. We provide evidence that key calendar days are good approximations of times when contact rates change and, therefore, are efficient periods for effective interventions particularly in places with low testing and lack of contact tracing. This has helped us to recreate different outbreaks of the COVID-19 disease dynamics in Mexico and Peru and explore the impact of hypothetical interventions that reduce the contact rate.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study used ONLY openly available human data that were originally located at: https://www.gob.mx/salud/documentos/datos-abiertos-152127 https://www.datosabiertos.gob.pe/dataset/casos-positivos-por-covid-19-ministerio-de-salud-minsa https://www.datosabiertos.gob.pe/dataset/fallecidos-por-covid-19-ministerio-de-salud-minsa
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
We acknowledge partial support from grants PAPIIT IN115720 and IV100220. JXVH developed part of this work during his sabbatical leave at the Simons Institute, University of Berkeley with partial support from a PASPA-UNAM fellowship.
CERHV and RHM acknowledge support from PAPIIT grant IG100221.
E-mail address: adrian.acuna{at}unison.mx
E-mail address: msantana{at}unam.mx
E-mail address: carloserwin{at}sigma.iimas.unam.mx
E-mail address: ramses{at}sigma.iimas.unam.mx
E-mail address: jx.velasco{at}im.unam.mx
Data Availability
All data produced in the present study are available upon reasonable request to the authors
